Ritter Pharmaceuticals has announced a public offering of class A units to raise $10m.
The US-based pharmaceutical company plans to use the funds for general corporate purposes, including research and development (R&D) programmes and working capital.
US-based Sienna Biopharmaceuticals plans to raise $74.75m through an initial public offering (IPO) of common stock shares.
Sienna plans to use the funds from the offering towards the development of SNA-120.
Exscientia has formed a strategic partnership with GlaxoSmithKline (GSK) to carry out drug programmes for the latter.
The artificial intelligence-based drug discovery company will undertake programmes aimed at discovering novel and selective small molecules for various targets identified by GSK.

US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAustralian life science company BARD1 Life Sciences has announced two offerings of 137 million common stock shares and 125 million shares priced at A$0.008 ($0.006) a share, to raise a total of A$2m ($1.6m).
BARD1 plans to use the funds towards R&D programmes and for general corporate purposes.